行情

PTI

PTI

Proteostasis
NASDAQ

实时行情|Nasdaq Last Sale

0.7300
-0.0040
-0.55%
已收盘, 16:06 10/17 EDT
开盘
0.7400
昨收
0.7340
最高
0.7700
最低
0.7270
成交量
121.32万
成交额
--
52周最高
10.38
52周最低
0.6100
市值
3,732.42万
市盈率(TTM)
-0.4746
分时
5日
1月
3月
1年
5年

分析师评级

4位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

PTI 新闻

  • Boehringer Ingelheim launches mid-stage study of new CF treatment
  • Seeking Alpha - Article.1天前
  • Vertex Enters Into Collaboration With Privately-Held Ribometrix
  • Zacks.10/02 14:29
  • Proteostasis Therapeutics to Present at the 2019 Cantor Global Healthcare Conference
  • PR Newswire.09/26 12:00
  • Did Proteostasis Therapeutics, Inc. (NASDAQ:PTI) Insiders Buy Up More Shares?
  • Simply Wall St..09/20 18:22

更多

所属板块

生物技术和医学研究
+0.95%
制药与医学研究
+0.61%

热门股票

名称
价格
涨跌幅

PTI 简况

Proteostasis Therapeutics, Inc. is a clinical stage biopharmaceutical company. The Company is engaged in the discovery and development of novel therapeutics to treat cystic fibrosis (CF), and other diseases caused by an imbalance in the proteostasis network, a set of pathways that control protein biosynthesis, folding, trafficking and clearance. The Company focuses on identifying therapies that restore protein function. The Company’s CF focused pipeline consists of novel CFTR modulators including correctors, potentiators and amplifiers. The Company’s clinical developments include PTI-801, a third generation CFTR corrector, PTI-808, a CFTR potentiator, and PTI-428, a CFTR amplifier.
展开

Webull提供Proteostasis Therapeutics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。